clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Wound Infection D014946 12 associated lipids
Bacteriuria D001437 7 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Periodontal Pocket D010514 9 associated lipids
Ischemia D007511 18 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Periodontitis D010518 22 associated lipids
Nasal Polyps D009298 26 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kunin M et al. Mycobacterium chelonae peritonitis in peritoneal dialysis. Literature review. 2014 Eur. J. Clin. Microbiol. Infect. Dis. pmid:24569948
Fan Y et al. High and low doses of clarithromycin treatment are associated with different clinical efficacies and immunomodulatory properties in chronic rhinosinusitis. 2014 J Laryngol Otol pmid:24555753
Hanson KE et al. Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing? 2014 J. Clin. Microbiol. pmid:24554745
Yakoob J et al. Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori. 2014 Microb. Drug Resist. pmid:23844851
Markert C et al. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. 2014 Br J Clin Pharmacol pmid:23738582
Khoshnood A et al. Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial. 2014 J Med Life pmid:25408735
Ueda Y et al. [Obstructive pneumonia and brain abscess due to Nocardia elegans in a patient with systemic lupus erythematosus]. 2014 Kansenshogaku Zasshi pmid:24974451
Negrín-González J et al. Psychiatric adverse reaction induced by clarithromycin. 2014 Eur Ann Allergy Clin Immunol pmid:24853570
Kurosaki Y et al. [Two cases of pulmonary Mycobacterium avium complex disease with resistance to clarithromycin]. 2014 Kekkaku pmid:24979948
Iwanaga K and Carter ER Mycobacterium abscessus complex lung infection in a toddler with a tracheostomy. 2014 Pediatr. Pulmonol. pmid:23460506
Tümgör G et al. Comparison of standard and standard plus vitamin E therapy for Helicobacter pylori eradications in children. 2014 Turk J Gastroenterol pmid:25910378
Çiftci İH et al. Comparison of FISH, RFLP and agar dilution methods for testing clarithromycin resistance of Helicobacter pylori. 2014 Turk J Gastroenterol pmid:25910373
Heo J and Jeon SW [Changes in the eradication rate of conventional triple therapy for Helicobacter pylori infection in Korea]. 2014 Korean J Gastroenterol pmid:24651586
Kang BK et al. [New therapeutic strategies against Helicobacter pylori]. 2014 Korean J Gastroenterol pmid:24651587
Lee JY and Kim N [Future trends of Helicobacter pylori eradication therapy in Korea]. 2014 Korean J Gastroenterol pmid:24651589
Lee SH et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. 2014 Ann Lab Med pmid:24422193
Patsche CB et al. Disseminated Mycobacterium celatum disease with prolonged pulmonary involvement. 2014 Int. J. Infect. Dis. pmid:25008771
Pathak V et al. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. 2014 Ann Am Thorac Soc pmid:24460438
Jesus FP et al. In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25001300
Wu JY et al. Evidence-based recommendations for successful Helicobacter pylori treatment. 2014 Expert Rev Gastroenterol Hepatol pmid:24410470
Díaz Cuevas Z et al. [Nodular skin lesions in a patient with rheumatoid arthritis under therapy with anti-tumor necrosis factor-α]. 2014 Med Clin (Barc) pmid:23877097
Mendu ML and Waikar SS Drug-drug interactions and acute kidney injury: caveat prescriptor. 2014 Am. J. Kidney Dis. pmid:24820318
Farley R et al. Antibiotics for bronchiolitis in children under two years of age. 2014 Cochrane Database Syst Rev pmid:25300167
Furuta T et al. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. 2014 J. Gastroenterol. Hepatol. pmid:24224808
Page SR and Yee KC Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. 2014 Intern Med J pmid:25041770
Noguchi S et al. Polymorphic transformation of antibiotic clarithromycin under acidic condition. 2014 J Pharm Sci pmid:24375227
Phillips RO et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. 2014 Antimicrob. Agents Chemother. pmid:24323473
McNicholl AG et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. 2014 Gut pmid:23665990
Rakici H et al. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. 2014 Digestion pmid:25547786
Karamanolis GP et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece. 2014 Digestion pmid:25531953
Hemphill A et al. Treatment of echinococcosis: albendazole and mebendazole--what else? 2014 Parasite pmid:25526545
Kawai T et al. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). 2014 J. Gastroenterol. Hepatol. pmid:25521730
Wang B et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. 2014 World J. Gastroenterol. pmid:25356059
Morakul B et al. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. 2014 Eur J Pharm Biopharm pmid:25201298
Parekh TM et al. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. 2014 JAMA Intern Med pmid:25179404
Kutluk G et al. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains? 2014 Eur J Gastroenterol Hepatol pmid:25171023
Higashi F et al. Additional treatment with clarithromycin reduces fever duration in patients with influenza. 2014 Respir Investig pmid:25169846
Lambert D et al. Gastritis due to Helicobacter pylori, an unusual cause of chronic diarrhoea in HIV infected patients. 2014 Med Mal Infect pmid:25015308
Teh X et al. Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. 2014 PLoS ONE pmid:25003707
Lyons J et al. An unusual lung mass post stem cell transplantation. 2014 Transpl Infect Dis pmid:24995624
Lee JW et al. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. 2014 Scand. J. Gastroenterol. pmid:24988873
Wang Y et al. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. 2014 Helicobacter pmid:24826809
Pan-In P et al. Ethyl cellulose nanoparticles: clarithomycin encapsulation and eradication of H. pylori. 2014 Carbohydr Polym pmid:24815396
Ichihara A et al. Case of disseminated cutaneous Mycobacterium chelonae infection mimicking cutaneous vasculitis. 2014 J. Dermatol. pmid:24801916
Togami K et al. Involvement of intestinal permeability in the oral absorption of clarithromycin and telithromycin. 2014 Biopharm Drug Dispos pmid:24801141
Bernut A et al. In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. 2014 Antimicrob. Agents Chemother. pmid:24798271
Adebisi AO and Conway BR Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus. 2014 Int J Pharm pmid:24792977
Bolhuis MS et al. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. 2014 Eur. Respir. J. pmid:24791826
Mark TM et al. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. 2014 Leuk. Lymphoma pmid:24576165
Takazono T et al. Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report. 2014 BMC Infect. Dis. pmid:24576098